ENDRA Life Sciences Inc (NDRA)
NASDAQ:NDRA
Want to see NDRA full AI Analyst Report?
NDRA Stock Chart & Stats
$4.69
-$0.12(-1.95%)
At close: 4:00 PM EST
$4.69
-$0.12(-1.95%)
Day’s Range― - ―
52-Week Range$2.96 - $11.96
Previous CloseN/A
Volume13.45K
Average Volume (3M)514.97K
Market Cap
$5.79M
Enterprise Value$4.24M
Total Cash (Recent Filing)$356.46K
Total Debt (Recent Filing)$461.21K
Price to Earnings (P/E)―
Beta1.31
Next Earnings
Aug 17, 2026EPS Estimate
-0.84Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-8.16
Shares Outstanding1,270,077
10 Day Avg. Volume1,472,495
30 Day Avg. Volume514,968
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)1.58
Price to Sales (P/S)0.00
P/FCF Ratio-0.69
Enterprise Value/Market Cap0.73
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-106.87
Enterprise Value/Ebitda-0.59
Forecast
1Y Price Target
$25.00Price Target Upside433.05% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-4.65
Revenue Forecast (FY)$100.00K
Bulls Say, Bears Say
Bulls Say
Proprietary TAEUS Imaging PlatformENDRA’s TAEUS Nexus is a proprietary diagnostic ultrasound platform focused on liver steatosis and fibrosis assessment. Owning differentiated imaging IP creates a durable product moat with potential device sales and recurring service/support revenue if clinical adoption progresses.
Modest LeverageReported TTM debt-to-equity of ~0.26 indicates low financial leverage, reducing near-term solvency pressure. Lower debt affords the company more optionality to pursue commercialization, partnerships, or strategic alternatives without immediate refinancing constraints.
Committed Strategic FinancingThe structured private placement (~$3.8M) with deposit control and an investor board observer provides tangible runway extension and governance oversight. This financing directly supports working capital and efforts to restore Nasdaq equity compliance, enabling continued execution of strategic options.
Bears Say
Zero RevenueENDRA has reported zero revenue while incurring sizable operating losses (TTM net loss ~-$7.3M). Lack of a repeatable revenue base means commercial product-market fit remains unproven, forcing reliance on external capital and raising execution risk for sustainable operations.
Sustained Cash BurnMaterial negative operating and free cash flow indicate ongoing high cash consumption. Persistent negative FCF necessitates frequent financing, increases dilution risk, reduces strategic flexibility, and constrains the company’s ability to invest in commercialization or clinical validation long-term.
Nasdaq Listing RiskA Nasdaq notice citing stockholders’ equity below the $2.5M threshold creates structural listing risk. Potential delisting would materially impair access to capital, reduce liquidity and institutional interest, and could force distressed financing or hurried strategic transactions that dilute shareholder value.
ENDRA Life Sciences News
NDRA FAQ
What was ENDRA Life Sciences Inc’s price range in the past 12 months?
ENDRA Life Sciences Inc lowest stock price was $2.96 and its highest was $11.96 in the past 12 months.
What is ENDRA Life Sciences Inc’s market cap?
ENDRA Life Sciences Inc’s market cap is $5.79M.
When is ENDRA Life Sciences Inc’s upcoming earnings report date?
ENDRA Life Sciences Inc’s upcoming earnings report date is Aug 17, 2026 which is in 63 days.
How were ENDRA Life Sciences Inc’s earnings last quarter?
ENDRA Life Sciences Inc released its earnings results on May 18, 2026. The company reported -$1.09 earnings per share for the quarter, missing the consensus estimate of N/A by -$1.09.
Is ENDRA Life Sciences Inc overvalued?
According to Wall Street analysts ENDRA Life Sciences Inc’s price is currently Undervalued.
Does ENDRA Life Sciences Inc pay dividends?
ENDRA Life Sciences Inc does not currently pay dividends.
What is ENDRA Life Sciences Inc’s EPS estimate?
ENDRA Life Sciences Inc’s EPS estimate is -0.84.
How many shares outstanding does ENDRA Life Sciences Inc have?
ENDRA Life Sciences Inc has 1,270,077 shares outstanding.
What happened to ENDRA Life Sciences Inc’s price movement after its last earnings report?
ENDRA Life Sciences Inc reported an EPS of -$1.09 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 7.129%.
Which hedge fund is a major shareholder of ENDRA Life Sciences Inc?
Currently, no hedge funds are holding shares in NDRA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
ENDRA Life Sciences Inc
ENDRA Life Sciences Inc. specializes in advancing the capabilities of clinical diagnostic ultrasound. The company's primary development is thermo-acoustic enhanced ultrasound technology, which operates by emitting sound waves that echo off internal body components such as tissues, organs, and blood. This innovation is utilized in managing nonalcoholic fatty liver disease, meticulously monitoring temperature during thermoablative surgical procedures, detailed vascular imaging, and assessing tissue perfusion. Furthermore, ENDRA offers other diagnostic imaging modalities, including computed tomography (CT), magnetic resonance imaging (MRI), and conventional ultrasound. These instruments empower physicians to visualize internal anatomy, aiding in treatment guidance and the identification of various medical conditions like bone fractures, cancerous growths, indicators of heart disease, or internal bleeding. The company also maintains a research collaboration agreement with General Electric Company. Established in 2007, ENDRA Life Sciences Inc. is headquartered in Ann Arbor, Michigan.
NDRA Stock 12 Month Forecast
Average Price Target
$25.00
▲(433.05% Upside)
Technical Analysis
Ownership Overview
31.76% Insiders
0.83% Mutual Funds
4.09% Other Institutional Investors
62.74% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---